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Abstract
Background: Proteinuria is one of the essential criteria for the clinical diagnosis of pre-eclampsia.
Increasing levels of proteinuria is considered to be associated with adverse maternal and fetal
outcomes. We aim to determine the accuracy with which the amount of proteinuria predicts
maternal and fetal complications in women with pre-eclampsia by systematic quantitative review of
test accuracy studies.
Methods: We conducted electronic searches in MEDLINE (1951 to 2007), EMBASE (1980 to
2007), the Cochrane Library (2007) and the MEDION database to identify relevant articles and
hand-search of selected specialist journals and reference lists of articles. There were no language
restrictions for any of these searches. Two reviewers independently selected those articles in
which the accuracy of proteinuria estimate was evaluated to predict maternal and fetal
complications of pre-eclampsia. Data were extracted on study characteristics, quality and accuracy
to construct 2 × 2 tables with maternal and fetal complications as reference standards.
Results: Sixteen primary articles with a total of 6749 women met the selection criteria with levels
of proteinuria estimated by urine dipstick, 24-hour urine proteinuria or urine protein:creatinine
ratio as a predictor of complications of pre-eclampsia. All 10 studies predicting maternal outcomes
showed that proteinuria is a poor predictor of maternal complications in women with pre-
eclampsia. Seventeen studies used laboratory analysis and eight studies bedside analysis to assess
the accuracy of proteinuria in predicting fetal and neonatal complications. Summary likelihood
ratios of positive and negative tests for the threshold level of 5 g/24 h were 2.0 (95% CI 1.5, 2.7)
and 0.53 (95% CI 0.27, 1) for stillbirths, 1.5 (95% CI 0.94, 2.4) and 0.73 (95% CI 0.39, 1.4) for
neonatal deaths and 1.5 (95% 1, 2) and 0.78 (95% 0.64, 0.95) for Neonatal Intensive Care Unit
admission.
Conclusion: Measure of proteinuria is a poor predictor of either maternal or fetal complications
in women with pre-eclampsia.
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Pre-eclampsia is associated with increased maternal and
fetal mortality and morbidity. Proteinuria is one of the
essential criteria for the clinical definition of pre-eclamp-
sia. It is part of the fundamental investigations performed
by healthcare professionals in primary and secondary care
to monitor disease severity and predict complications in
women with pre-eclampsia. Urinalysis by visual reagent
strip tests is widely performed in antenatal clinics and in
the community by various health professionals. Total pro-
tein estimation in a 24-hour urine sample is also fre-
quently used to assess the severity of pre-eclampsia in
patients admitted to the hospital. More recently, spot
urine protein:creatinine ratio has been used to provide an
accurate quantification of 24-hour proteinuria [1]. Esti-
mation of the accuracy of the predictive value of proteinu-
ria by any of the above methods in predicting maternal
and fetal complications will aid in clinical management
by identifying the highest risk women who may need
aggressive management, and the lower risk women in
whom unnecessary interventions may be avoided.
Proteinuria occurs due to renal glomerular endotheliosis,
a manifestation of widespread endothelial damage in pre-
eclampsia [2,3]. The association between proteinuria and
adverse fetal outcomes was first highlighted by Page and
Christianson [4]. Since then, increased excretion of pro-
tein in women with pre-eclampsia has been generally
associated with adverse maternal and fetal outcomes [5-
7]. However, the primary diagnostic studies that evaluate
the association between increase in the levels of proteinu-
ria and maternal and neonatal outcomes have not gener-
ally been conducted with sufficiently large sample size to
provide precise accuracy estimates. Moreover, they vary
widely in their definition of pre-eclampsia, maternal and
fetal outcomes, the method used for measurement and
optimal cut-off levels of proteinuria. There are no system-
atic reviews exploring the accuracy of proteinuria to pre-
dict complications of pre-eclampsia. We therefore
conducted a comprehensive systematic review to obtain
precise estimates of likelihood ratios of adverse maternal
and fetal complications for various cut-off levels of pro-
teinuria in women with pre-eclampsia.
Methods
Data Sources
The review was carried out with a prospective protocol
using widely recommended methods [8-12]. We searched
MEDLINE (1951 to 2007), EMBASE (1980 to 2007),
Cochrane Library (2007) and MEDION (a database of
diagnostic test reviews set up by Dutch and Belgian
researchers) for relevant citations. A search term combina-
tion was constructed after exhaustive planning and pilot-
ing of possible search concepts capturing the relevant
population, tests and outcomes. Our search terms are
shown in Additional file 1. An initial search in Medline
yielded 11,711 citations. The search strategy was adapted
for searching in Embase to obtain a total of 19,500 cita-
tions. From this citation set, studies were selected for
inclusion in the review in a two-stage process if they stud-
ied the accuracy of proteinuria in the prediction of mater-
nal and fetal complications in women with pre-eclampsia.
The reference lists of all known primary and review arti-
cles were examined to identify cited articles not captured
by electronic searches. Language restrictions were not
applied. A comprehensive database of relevant articles
was constructed.
Study Selection
Studies which evaluated the accuracy of proteinuria in
women with pre-eclampsia for the prediction of maternal
or fetal complications were selected in a two-stage proc-
ess. We included studies that pre-specified the patients to
have pre-eclampsia, used bedside (urine dipstick) or lab-
oratory methods (24-hour protein estimation, urine pro-
tein:creatinine ratio) to measure levels of proteinuria and
assessed maternal or fetal clinical complications as out-
come. First, the electronic searches were scrutinised and
full manuscripts of all citations that were likely to meet
the predefined selection criteria were obtained. Second,
final inclusion or exclusion decisions were made by the
reviewers (ST and FOM) after examination of these man-
uscripts. Studies which met the predefined and explicit
criteria regarding population, tests, outcomes and study
design (Additional file 2) were selected for inclusion in
the review. When disagreements occurred, they were
resolved by consensus (ST, KI and FOM). In cases of
duplicate publication, the most recent and complete ver-
sions were selected. There were no language restrictions.
Information was extracted from each selected article on
study characteristics, quality and accuracy results. Accu-
racy data were used to construct 2 × 2 tables of proteinuria
result (test positive if proteinuria levels were above the
threshold defined in the primary study, and test negative
if these were below the threshold) and maternal and fetal
outcomes.
Methodological quality assessment
All manuscripts meeting the selection criteria were
assessed for their methodological quality. Quality was
defined as the confidence that the study design, conduct
and analysis minimised bias in the estimation of test accu-
racy. Based on existing checklists [13,14], quality assess-
ment involved scrutinizing study design and relevant
features of the population, test and outcomes of the study.
A study was considered to be of good quality if it used a
prospective design, consecutive enrolment, full verifica-
tion of the test result with reference standard, and had
adequate test description. We excluded studies with case-Page 2 of 9
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bias [13].
Data synthesis
Likelihood ratios (LRs) for positive and negative test
results were calculated for each study, separately for each
test threshold. Summary LRs were then computed where
appropriate for positive and negative test results for each
individual test threshold and for each outcome of interest.
This information is clinically more relevant than tradi-
tional summaries of accuracy such as sensitivity and spe-
cificity, as LRs allow the estimation of post-test
probabilities of various complications for women at dif-
ferent risk levels [15]. The LR indicates by how much a
given test result raises or lowers the probability of having
the disease. The higher the LR of an abnormal test, the
greater is the value of the test. Conversely, the lower the LR
of a normal test, the greater is the value of the test. An LR
of >10 or <0.1 is regarded as 'very useful' test accuracy,
whilst an LR of 5 to 10 or 0.1 to 0.2 is regarded as 'moder-
ately useful', and an LR of 2 to 5 or 0.2 to 0.5 is regarded
as 'somewhat useful'. An LR of 1 to 2 or 0.5 to 1 is only
regarded as 'little useful' and an LR of 1 as 'useless'.
Although, this categorization is useful for interpretation
of LRs, it should be noted that the value of a test may vary
depending on the pre-test probability of the condition,
and the consequences of treatment.
Heterogeneity of diagnostic odds ratio (dOR) was
assessed graphically using forest plot [16] (not shown)
and statistically using chi-squared test [17] to aid in deci-
sions on how to proceed with quantitative synthesis [18].
As, for some tests and outcomes, there was either graphi-
cal or statistically significant heterogeneity, we used ran-
dom effects model meta-analysis [17]. Where a
quantitative approach was not appropriate due to signifi-
cant clinical heterogeneity, we refrained from pooling and
the results are described narratively and the LR of mater-
nal and fetal complication estimated in each study is
reported. All statistical analyses were performed using
Meta Disc statistical package.
Results
Literature identification and study quality
Figure 1 summarizes the process of literature identifica-
tion and selection. There were 16 primary articles that met
the selection criteria including a total of 6749 women
(Figure 1) [1,19-34]. Eight articles reported estimation of
proteinuria by laboratory method only
[20,21,23,26,28,29,33,34], five by bedside dipstick uri-
nalysis only [22,24,25,30,32], two by either of the above
methods [27,31] and one by spot urine protein:creatinine
ratio [1]. The salient features (population subgroups, test
characteristics and reference standards) of each individual
study can be obtained from the authors. The definition of
pre-eclampsia differed widely between the studies. The
test threshold in individual studies for laboratory estima-
tion varied from 0.3 g/24 h to 10 g/24 h, or was reported
as an increase in proteinuria by 2 g/24 h between two
measurements. The cut-off levels for bedside urinalysis
using visual reagents ranged from 1+ to 4+ of proteinuria.
One study evaluated the accuracy of spot urine protein:
creatinine ratio for threshold levels of 500 mg/mmol and
900 mg/mmol in the prediction of maternal and fetal
complications [1]. The methodological quality of the
included studies is given in Figure 2.
Proteinuria to predict maternal outcomes
Three test accuracy studies evaluated the accuracy of pro-
teinuria in predicting eclampsia for cut off levels of 5 g/24
h, 10 g/24 h and an increase by 2 g in 24 hours [23,26].
The LR of positive test ranged from 1.7 (95% CI 0.94, 3.1)
to 2.7 (95% CI 1.1, 6.2) respectively. The negative LR
ranged from 0.41 (95% CI 0.04, 4.5) to 0.62 (95% CI
0.28, 1.4) (Figure 3).
Two studies estimated the accuracy of proteinuria in pre-
dicting placental abruption using a cut-off of increase in
level more than 2 g/24 h [23,29]. The pooled positive and
negative LRs for the above cut-off were 0.88 (95% CI 0.42,
1.86) and 1.1 (95% CI 0.75, 1.6) respectively (Figure 3).
HELLP syndrome prediction was evaluated in four test
accuracy studies [23,26,29]. The pooled estimate of LRs
for positive and negative test for a cut-off of increase in
levels more than 2 g in 24 hours were 0.86 (95% CI 0.38,
2) and 1.1 (95% CI 0.74, 1.6) respectively (Figure 3).
Proteinuria to predict fetal outcomes
Fetal, neonatal and perinatal mortality
Thirteen studies reported prediction of fetal, neonatal and
perinatal mortality using both laboratory and bedside
testing for proteinuria [1,20,21,23,26,28-30,34]. The
pooled LRs for positive and negative test for a cut-off of 5
g/24 h as reported in three studies [20,21,23] were 2 (95%
CI 1.5, 2.7) and 0.53 (95% CI 0.27, 1) respectively (Figure
4). The largest study, involving 3260 patients, that esti-
mated the prediction of stillbirths in pre-eclampsia was
conducted by Taylor et al using urine dipstick method
[35].
Neonatal deaths were evaluated in five studies for cut-off
levels of 5 g/24 h (n = 3) [20,21,26], 10 g/24 h (n = 1) [26]
and increase by 2 g in 24 h (n = 1) [23]. The pooled esti-
mates of LR+ and LR- for proteinuria threshold of 5 g/24
h were 1.5 (95% CI 0.94, 2.4) and 0.73 (95% 0.39, 1.4)
respectively.
The threshold levels of proteinuria to predict perinatal
deaths were 1 g/l, 2 g/l and 500 mg/mmol. The positive LRPage 3 of 9
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(95% CI 0.14, 2.2) for cut-off levels of 500 mg/mmol [1].
Small for gestational age
Four studies assessed the accuracy of bedside urinalysis for
cut-offs of 1+, 2+ and 3+ of proteinuria in urine dipstick
[22,24,27]. The pooled positive and negative LRs for 3+ of
proteinuria were 1.6 (95% CI 1.1, 2.3) and 0.75 (95% CI
0.59, 0.96) respectively. The likelihood ratio of laboratory
estimates of proteinuria levels of 0.3 g/24 h and 0.5 g/24
h were 0.96 (95% CI 0.75, 1.2) and 1.7 (95% CI 1.1, 2.7)
for positive test and 1.09 (95% 0.63, 1.9) and 0.73 (95%
CI 0.52, 1) for negative test respectively, using the benze-
thonium chloride assay (BCA) [33]. For tests performed
on the same patients using the Bradford assay Waugh et al
report positive likelihood ratios of 1.71 (95% CI 1.0, 2.9)
and 2.79 (95% CI 1.4, 5.5) for cut-off levels of 0.3 g/24 h
and 0.5 g/24 h respectively [33].
Study selection process for systematic review of proteinuria to predict maternal and fetal complicationsFigure 1
Study selection process for systematic review of proteinuria to predict maternal and fetal complications.
Total citations identified from electronic searches             n= 541
Articles of accuracy of proteinuria in predicting maternal and fetal complications in 
women with pre eclampsia retrieved for detailed evaluation n=173
From electronic searches                            n= 163
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Primary articles included in systematic review                  n=16
Citations excluded after screening titles and/or abstracts: n= 378
Articles excluded with reasons
Inappropriate population                                        n=47
Data not extractable                                            n=48
Inappropriate outcome - n=10
Lack of original data i.e. reviews or letters                   n=9
Inappropriate test  
Case control studies               
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Total excluded                                                  n=157 Page 4 of 9
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NICU admission was assessed as an outcome in five stud-
ies [20,23,24,26]. The pooled positive and negative LRs
for cut-off level of 5 g/24 h were 1.5 (95% CI 1, 2) and
0.78 (955 CI 0.64, 0.95) and for levels of 10 g/24 h, the
LRs were 5.6 (95% CI 1.8, 17.4) and 0.77 (95% CI 0.69,
0.87) respectively.
Discussion
Proteinuria has usually been associated with increase in
maternal and fetal mortality and morbidity [7]. Our
review has shown that the magnitude of proteinuria in
women with pre-eclampsia is a poor predictor of the
major maternal and fetal complications.
For prediction of adverse fetal outcomes, the only statisti-
cally significant results were observed for positive test
result with LR+ ranging from 1.3 to 2.3 for cut-off levels of
5 g/24 h, 1+ and 3+ proteinuria in the prediction of still-
births [20,21,23,30]. Furthermore, we need to take into
account that three of these five test accuracy studies were
conducted more than 30 years ago [21,30]. The test was
found to be a poor predictor of neonatal and perinatal
deaths with no significant LRs for positive or negative test.
The test performed poorly as evidenced by the increase in
adverse events noticed in the test negative group com-
pared with the test positive group, as noticed in some
studies [23,28,33]. The overall low value of abnormal test
and high value of normal test implies that the test is of
'very little' clinical value.
The validity of our review findings depends on the meth-
odology of the systematic review and the quality of the
individual studies included [13]. An extensive literature
search was performed in relevant databases without any
language restrictions to minimize the possibility of miss-
ing any studies. Methodological deficiencies such as veri-
fication bias, differential use of reference standards and
case-control design did not apply to the studies in the
review, ensuring inclusion of studies of acceptable quality.
The methodological problems facing reviews of this
nature are daunting. A significant limitation of this review
is the heterogeneity noticed between individual studies
with regards to population, definition of pre-eclampsia,
method of performing the test, test thresholds, frequency
of testing, interval between the test and outcome, and ref-
erence standards. The lack of information regarding the
temporal relation between test findings and outcomes
observed and possibility of confounding by other risk fac-
tors contributing to maternal and fetal complications may
influence the observed predictive value of proteinuria for
maternal and fetal complications. The wide confidence
intervals observed for the various outcomes are a reflec-
tion of the statistical uncertainty around the results due to
the small sample size in many studies. Meta-analysis of
studies using individual patient data may conquer many
of the difficulties identified.
Conclusion
This systematic review has shown that estimation of levels
of proteinuria in women with is not a clinically useful test
to predict fetal or maternal complications. The results of
this review calls into question the commonly used prac-
tice of making clinical decisions in women with pre-
eclampsia based on the severity of proteinuria. It has high-
Quality of the included primary studies in the systematic review of accuracy of proteinuria in predicting complications in women wi  pre-eclampsiaFigure 2
Quality of the included primary studies in the systematic review of accuracy of proteinuria in predicting com-
plications in women with pre-eclampsia.
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ies on this important question with the hope to expand
future research.
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Likelihood ratios for maternal outcomes in women with pre-eclampsia for various threshold levels of proteinuriaFigure 3
Likelihood ratios for maternal outcomes in women with pre-eclampsia for various threshold levels of proteinu-
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Likelihood ratios for fetal outcomes in women with pre-eclampsia for various threshold levels of proteinuriaFigure 4
Likelihood ratios for fetal outcomes in women with pre-eclampsia for various threshold levels of proteinuria.
 
1.4 (0.87–2.1)
1.4 (0.87–2.2)
Lao 1988
Odegaard 2000 
Buchbinder 2002
307
107
87
307
0.63 (0.25–1.6)
0.72 (0.53–0.97)
0.61 (0.3–1.24)
Odegaard 2000 
Lao 1988 87
Buchbinder 2002 107
0.78(0.62–0.97)Newman 2002 209
0.77 (0.69–0.87)Newman 2002 209
NICU admission
Small for gestational age
Waugh 2005 0.73 (0.52-1.0)195
Waugh 2005 1.09 (0.63-1.9)195
Furukawa 2006 79 0.82 (0.55–1.2)
Hall 2002 0.78 (0.47-1.3)340
2+
5g/24h
1+
3+
1+
5g/24h
10g/24h
0.5g/24h
0.3g/24h
Increase by 
2g/24h
Pooled LR 0.75 (0.59 – 0.96)
p=0.595
Pooled LR 0.78 (0.64 – 0.95)
p=0.966
10.1 10  
Likelihood ratio
LR -(95% CI)NumberCut off Study Year
Hall 2002
0.54 (0.24-1.2)
0.66 (0.16-2.6)
0.21 (0.02-2.8)107
99Fleigner 1975
340
Paladini 1970
Newman 2002 
0.82 (0.52-1.3)
1 (0.8-1.4)
0.73 (0.35-1.5)
379
209
209Newman 2002
Buchbinder 2002 
Taylor 1954
Taylor 1954
0.76 (0.70-0.84)
0.69 (0.59-0.82)
3260
3260
0.43 (0.04-4.8)107Buchbinder 2002 
99Fleigner 1975 0.85 (0.21-3.4)
Hall 2002 74 1.5 (0.98-2.3)
Paladini 1970 1.0 (0.83-1.2)379
Stillbirths
Neonatal deaths
0.55 (0.14-2.2)321Chan 2005
Perinatal deaths
5g/24h
5g/24h
1g/l
10g/24h
1+
3+
Increase by 
2g/24h
2g/l
500mg/mmol
Pooled LR 0.53 (0.27-1)p=0.719
Pooled LR 0.73 (0.39-1.4)
p=0.884
546
415
386
0.78 (0.52–1.2)
0.61 (0.23–1.6)
0.45 (0.21–0.96)
1.8 (1.1-2.8)
2.1 (0.51-8.3)
2.2 (1.4-3.3)
1.8 (0.67-4.6)
0.96 (0.77-1.2)
1.4 (0.76-2.6)
2.3 (1.9-2.7)
1.3 (1.2-1.4)
1.8 (0.79-4.1)
1.2 (0.3-5)
0.31 (0.02-4.1)
1.0 (0.72-1.4)
5.3 (1.3-22.1)
2.0 (1.5-2.7)
p=0.789
1.5 (0.94-2.4)
p=0.378
10.1 10  
Likelihood ratio
1.7 (1.1-2.7)
0.96 (0.75-1.2)
1.4 (0.78-2.5)
1.6 (1.1 – 2.3)
p=0.241
1.5 (1 – 2)
p=0.617
1.6 (0.96–2.7)
5.6 (1.8–17.4)
1.6 (0.86–2.8)
1.3 (1.1–1.5)
1.9 (1.3–2.8)
1.4 (0.95–2.1)
1.3 (0.78–2.1)
LR +(95% CI)
5g/24h
5g/24h
3+
5g/24h
BMC Medicine 2009, 7:10 http://www.biomedcentral.com/1741-7015/7/10Additional material
Acknowledgements
The members of the TIPPS (Tests In Prediction of Pre-eclampsia's Severity) 
review group are: Shakila Thangaratinam (Clinical Lecturer/Specialist Reg-
istrar), Arri Coomarasamy (Senior Lecturer/Consultant in Gynaecology) 
and Khalid S Khan (Professor in Obstetrics and Gynaecology) affiliated to 
Academic Unit, Birmingham Women's Hospital, Birmingham, B15 2TG, UK. 
Khaled MK Ismail (Senior Lecturer/Consultant), Fidelma O'Mahony (Senior 
Lecturer/Consultant) and Shaughn O'Brien (Professor in Obstetrics and 
Gynaecology) affiliated to Academic Unit of Obstetrics and Gynaecology, 
Keele University School of Medicine, University Hospital of North Stafford-
shire, Stoke-on-Trent, ST4 6QG, UK. Steve Sharp (Electronic Information 
Librarian) affiliated to NeLH Specialist Library for ENT and Audiology, Rad-
cliffe Infirmary, Oxford, OX2 6HE, UK. Funding was provided by University 
Hospital North Staffordshire Research and Development Department, 
Stoke-on-Trent, UK. (Ref No. R 5177680).
References
1. Chan P, Brown M, Simpson J, Davis G: Proteinuria in pre-eclamp-
sia: how much matters?  BJOG 2005, 112:280-285.
2. Pollak VE, Nettles JB: The kidney in toxemia of pregnancy: a
clinical and pathologic study based on renal biopsies.  Medicine
(Baltimore) 1960, 39:469-526.
3. Spargo B, McCartney CP, Winemiller R: Glomerular capillary
endotheliosis in toxemia of pregnancy.  Arch Pathol 1959,
68:593-599.
4. Page EW, Christianson R: The impact of mean arterial pressure
in the middle trimester on the impact of pregnancy.  Am J
Obstet Gynecol 1976, 125:740-746.
5. American College of Obstetrics and Gynecology: Diagnosis and
management of preeclampsia and eclampsia.  In Practice bulle-
tin No.: 33 Washington (DC), American College of Obstetrics and
Gynecology; 2002. 
6. Cunningham FG: Hypertensive disorders of pregnancy.  In Wil-
liams' Obstetrics New York: McGraw-Hill; 2001:567-618. 
7. Ferazzani S, Caruso A, De Carolis S, Martino IV, Mancoso S: Pro-
teinuria and outcome of 444 pregnancies complicated by
hypertension.  Am Journal Obstet Gynecol 1990, 162:366-371.
8. Irwig LM, Tosteton AN, Gatsonis CA, Lao J, Colditz G, Chalmers TC,
Mosteller Fl: Guidelines for meta-analyses evaluating diagnos-
tic tests.  Ann Intern Med 1994, 120:667-676.
9. Cochrane Methods Working Group: Systematic Reviews of
Screening and Diagnostic Tests: Recommended Methods.
1996.
10. Deeks JJ: Systematic reviews in health care: Systematic
reviews of evaluations of diagnostic and screening tests.  BMJ
2001, 323:157-162.
11. Khan KS, Dinnes J, Kleijnen J: Systematic reviews to evaluate
diagnostic tests.  J Obstet Gynecol Reprod Biol 2001, 95:6-11.
12. Thangaratinam S, Coomarasamy A, Sharp S, O'Mahony F, O'Brien S,
Ismail KMK, Khan KS: Tests for predicting complications of pre-
eclampsia: A protocol for systematic reviews.  BMC Pregnancy
Childbirth 2008, 8:38.
13. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, Meulen JHP
van der, Bossuyt PM: Empirical evidence of design-related bias
in studies of diagnostic tests.  JAMA 1999, 282:1061-1066.
14. Rennie D: Improving reports of diagnostic tests: the STARD
initiave.  JAMA 2003, 289:89-90.
15. Jaeschke R, Guyatt GH, Sackett DL: Users' guide to the medical
literature. III. How to use an article about a diagnostic test.
B. What are the results and will they help me in caring for
my patients?  JAMA 1994, 271:703-707.
16. DerSimonian R, Laird N: Meta-analysis in clinical trials.  Control
Clin Trials 1986, 7:177-188.
17. Sutton AJ, Abrams KR, Jones DR, Sheldon TJ, Song F: Systematic
reviews of trials and other studies.  Health Technol Assess 1998,
2:1-276.
18. Greenland S: Quantitative methods in the review of epidemi-
ologic literature.  Epidemiol Rev 1987, 9:1-30.
19. Brown MA, Buddle ML: Hypertension in pregnancy: Maternal
and fetal outcomes according to laboratory and clinical fea-
tures.  Med J Aust 1996, 165:360-365.
20. Buchbinder A, Sibai BM, Caritis S, MacPherson C, Hauth J, Lindheimer
MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis
P, Thurnau G, National Institute of Child Health and Human Devel-
opment Network of Maternal-Fetal Medicine Units: Adverse peri-
natal outcomes are significantly higher in severe gestational
hypertension than in mild preeclampsia.  Am J Obstet Gynecol
2002, 186:66-71.
21. Fliegner J-RH: Placental function and renal tract studies in pre
eclampsia with proteinuria and long term maternal conse-
quences.  Am J Obstet Gynecol 1976, 126:211-217.
22. Furukawa S, Sameshima H, Ikenoue T: Intrapartum late deceler-
ation develops more frequently in pre-eclamptic women
with severe proteinuria.  J Obstet Gynaecol Res 2006, 32:68-73.
23. Hall DR, Odendaal HJ, Steyn DW, Grove D: Urinary protein
excretion and expectant management of early onset, severe
pre-eclampsia.  Int J Gyn Obstet 2002, 77:1-6.
24. Lao TT, Chin R-KH, Lam YM: The significance of proteinuria in
pre-eclampsia; proteinuria associated with low birth weight
only in pre-eclampsia.  Eur J Obstet Gynecol Reprod Biol 1988,
29:121-127.
25. Martin JN Jr, May WL, Magann EF, Terrone DA, Rinehart BK, Blake
P-G: Early risk assessment of severe preeclampsia: Admis-
sion battery of symptoms and laboratory tests to predict
likelihood of subsequent significant maternal morbidity.  Am
J Obstet Gynecol 1999, 180:1407-1414.
26. Newman MG, Robichaux AG, Stedman CM, Jaekle RK, Todd FM,
Dotson T, Lewis TF: Perinatal outcomes in preeclampsia that
is complicated by massive proteinuria.  Am J Obstet Gynecol
2003, 188:264-268.
27. Odegaard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R: Preec-
lampsia and fetal growth.  Obstet Gynecol 2000, 96:950-955.
28. Paladini A, Frollo G, Nappi G: (Clinical-statistical study on the
hypertension-edema-nephrosis syndrome. II. Sequelae for
the fetus, particular attention to perinatal mortality).  Arch
Ostet Ginecol 1970, 75:297-306.
29. Schiff E, Friedman SA, Kao L, Sibai BM: The importance of urinary
protein excretion during conservative management of
severe preeclampsia.  Am J Obstet Gynecol 1996, 175:1313-1316.
30. Taylor HC Jr, Tillman AJ, Blanchard J: Fetal losses in hypertension
and preeclampsia. I. An analysis of 4432 cases.  Obstet Gynecol
1954, 3:225-239.
31. Thurnau GR, Dyer A, Depp-III OR, Martin AO: The development
of a profile scoring system for early identification and sever-
ity assessment of pregnancy-induced hypertension.  Am J
Obstet Gynecol 1983, 146:406-416.
32. von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ains-
worth LM, Yin R, Norena M, Walley KR, Gruslin A, Moutquin JM, Lee
Additional file 1
Table S1. 
Search term combinations for identification of studies predicting com-
plications of pre eclampsia.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-10-S1.doc]
Additional file 2
Table S2. 
Study characteristics of the trials included in the systematic review of 
accuracy of proteinuria in predicting complications in women with 
pre-eclampsia.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-10-S2.doc]Page 8 of 9
(page number not for citation purposes)
BMC Medicine 2009, 7:10 http://www.biomedcentral.com/1741-7015/7/10Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
SK, Russell JA: The prediction of adverse maternal outcomes
in preeclampsia.  J Obstet Gynaecol Can 2004, 26:871-880.
33. Waugh J, Bell SC, Kilby MD, Lambert P, Shennan A, Halligan A: Urine
protein estimation in hypertensive pregnancy: which thresh-
olds and laboratory assay best predict clinical outcome?
Hypertens Pregnancy 2005, 24:291-302.
34. Weenink GH, Treffers PE, Vijn P: Plasma antithrombin III levels
in pre-eclampsia. Clinical and Experimental Hypertension –
Part B.  Hypertens Pregnancy 1983, 2:145-162.
35. Taylor HC Jr, Tillman AJ, Blanchard J: Fetal losses in hypertension
and in pre-eclampsia. II. Prognosis for the fetus according to
the week of gestation.  Obstet Gynecol 1954, 3:371-384.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/7/10/prepubPage 9 of 9
(page number not for citation purposes)
